CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...
Beginning June 1, 2020 all 5 CTS laboratories will being transitioning from the Grifols Procleix Ult...
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...